ReviewJGH open : an open access journal of gastroenterology and hepatology2026
Acute Kidney Injury in Patients With Cirrhosis Exposed to Iodinated Contrast: A Systematic Review and Meta-Analysis.
Review in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Iodinated radiocontrast agents are widely used in diagnostic radiography and therapeutic procedures. However, concerns remain regarding their association with contrast-induced acute kidney injury (CI-AKI) and contrast-associated acute kidney injury (CA-AKI). While these risks are frequently discussed in the general population, data on CI and CA-AKI in patients with cirrhosis remains limited. Aims: Evaluate the incidence and risk factors associated with CI-AKI or CA-AKI in patients with cirrhosis exposed to iodinated contrast (IC). Methods: A systematic search was conducted in PubMed, Embase, and Cochrane Central for studies including patients with cirrhosis exposed to IC. Binary endpoints were assessed using pooled odds ratios (OR), and continuous endpoints using mean differences (MDs) or standardized mean differences (SMDs). The primary outcome was the pooled incidence of AKI in patients with cirrhosis exposed to IC, with secondary outcomes including the risk of CI-AKI compared to unexposed patients and risk factors associated with CA-AKI development. Analyses were performed in R (version 4.3.2). Results: Nine observational studies were included, two of which used propensity score matching, encompassing a total of 2389 patients with cirrhosis, of whom 1672 were exposed to IC. The pooled incidence of acute kidney injury was 11.1% (95% CI 5.3%-18.8%). On the leave-one-out analysis, patients with cirrhosis receiving IC had a higher risk of AKI compared to those not receiving IC (OR 2.5; 95% CI 1.4-4.4). The presence of ascites was significantly associated with the development of CA-AKI (OR 3.2; 95% CI 1.8-5.5). Those who developed CA-AKI had significantly higher baseline MELD scores, associated with higher serum bilirubin and INR levels. Conclusion: Patients with cirrhosis exposed to IC agents had a higher risk of developing acute kidney injury compared to those not exposed. The development of CA-AKI was significantly associated with the presence of ascites and elevated baseline MELD scores, along with higher serum bilirubin and INR levels.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.